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     The aim of this investigation was conducted to proteomic analysis of plasma obtained from pregnant 
women who destined to develop late-onset preeclampsia without intrauterine growth restriction (IUGR) 
during 16
th
 week of gestation. Plasma was obtained from primiparous women during 16
th
 week of 
gestation. 2-DE proteomic analysis was done for plasma from 11 healthy pregnant women and 11 
women who developed preeclampsia later. Using bioinformatic analysis with Progenesis SameSpots 
ver4.0 software and ANOVA test, expression of 2 spots were statistically different between two groups. 
In preeclamptic state, expression of both were decreased, one of these spots was vitamin D binding 
protein (p-value: 0.047), the other one will be discussed in another paper. According to results, we 
concluded that during 16
th
 week of gestation, occurance of late-onset preeclampsia without IUGR is 
predictable. During this week, pathology of disease is present and may be the process of placental 
degeneration and impaired placentation are include in disease pathology. 
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INTRODUCTION 
     Preeclampsia (PE) is a complex multi-
systemic syndrome characterized by 
hypertension and pregnancy-induced 
proteinuria. In all cases, the only effective 
treatment is delivery. Delivery leads in recovery 
that reflects the key role of placental factors in 
pathogenesis of disease. This disease is a 
leading cause of mothers mortality and 
morbidity [1-4] and throughout the world, 
affects 3-8% of pregnant women [4-6] and 
annually, affects more than 8million mothers 
and causes the death of more than 70000 
mothers [7], generally, 10-15% of mothers 
mortality is directly related to preeclampsia and 
eclampsia, this disease affects 3-7% of 
nulliparous and 1-3% of multiparous pregnant 
women [4]. In Iran, the prevalence of severe 
preeclampsia is 3% and this disease causes 
18.2% of mothers mortality and 12% of preterm 
deliveries [8]. The complications of this disease 
for mothers include: disseminated 
coagulopathy, acute renal failure, liver damage, 
pulmonary edema and convulsion (in 
eclampsia). May the infants of preeclamptic 
mothers be affected: one third has preterm birth, 
20% of them have intrauterine growth 
restriction (IUGR) and prenatal death increases 
3-10 times [9], oligohydramnious and placenta 
previa also occur [1]. 
Preeclampsia is associated with diseases that 
occur in future, including hypertension, stroke 
ischemic heart disease [4, 10, 11]. Risk factors 
of PE includes nulliparity [4, 9, 12], multiple 
pregnancies [1,4], previous PE [4, 9], mother's 
age> 35 years [4], to be born in Africa continent 
[4], mole pregnancies [4] and fetal congenital 
abnormalities [4], living in high altitudes [4], 
obesity [4, 13, 14], mother's co-existed disease 
related to pathophysilogy of PE, including 
 




chronic hypertension, renal disease, diabetes 
(type 1 and 2), systemic lupus erythematous and 
thrombophilia [4, 15-17], immunologic 
interactions between parents [4], genetic 
predisposition [18]. 
Based on phenotype, PE can be classified into 
two subgroups of early-onset and late-onset or 
with and without IUGR [19-21]. In Iran, the 
prevalent phenotype is late-onset without 
IUGR [8]. 
According to above mentioned materials, it is 
beneficial to find screening biomarker(s) for 
PE, when the disease has not been established 
well or there is not any signs or symptoms of 
PE. The first step in biomarker determination 
is biomarker discovery and proteomics study is 
a way for this purpose. In this study, 
differences in the plasma proteome of healthy 
pregnant women and pregnant women destined 
to late-onset PE without IUGR was analyzed 
using 2 dimensional electrophoresis proteomic 
technique. This study was done during 16
th
 
week of gestation when there is no signs and 
symptoms of PE. 
 
METHODS 
Patients and phlebotomy 
    This case/control study was done in 16
th
 
week of gestation for primiparous women. In 
this study, blood samples of healthy pregnant 
women and pregnant women destined to late-
onset PE without IUGR, was collected in the 
16
th
 week of pregnancy. Written consent was 
obtained before phlebotomy. The case group 
was pregnant women destined to late-onset PE 
without IUGR. The disease was diagnosed by 
an obstetrics and gynecologic specialist  using 
the criteria of preeclampsia, the criteria of 
preeclampsia was diastolic blood pressure > 90 
mmHg and systolic blood pressure > 140 
mmHg in two times with 4 hours interval and 
one of these symptoms: proteinuria ≥ 0.3 g/24h 
or ≥ 2+ using dipstick or symptoms indicative 
of PE, including edema, epigaster pain and 
neurologic signs. 
Neonates were declared IUGR whom birth 
weight was lower than 10
th
 percentile for that 
gestational age. 
The control group was healthy pregnant 
women BMI matched with case group, these 
women were normotensive and their children 
were not IUGR. Phlebotomy was done in 16
th
 
week of gestation. During venipuncture 
sampling, 4.5 ml EDTA blood was drawn [22-
25]. Phlebotomy was done in Vali-asr Hospital 
which belongs to Tehran University of Medical 
Sciences. 
Exclusion criteria was hypertension and 
proteinuria before 20
th
 week of gestation, 
immunologic diseases, diabetes mellitus, 
multiple pregnancies, women with Body Mass 
Index (BMI) >30 on admission and women 
with IUGR pregnancy (is used for neonates 




Plasma samples preparation 
    Blood collection was  done by venipuncture 
rout and using needle with gauge 2°C (25-29), 
samples were collected in EDTA tubes and in 
less than 2 hours were centrifuged in 4ºC with 
3000 rpm and 8 minute durance. The separated 
plasma was again centrifuged with above 
conditions. Five X 150 µl aliquots were 
prepared from each sample and the remainder 
was divided in 500 µl aliquots. Microtubes 
were immediately placed in -80ºC freezer. The 
entire process, from phlebotomy to placing 
plasma samples in freezer, was done in 4 hours 
[22-24, 30-34]. 
Using ProteoPrepImmunoDepletion20 Kit and 
according to its direction, aboundant proteins 
were depleted from plasma samples. These 
proteins were: Albumin, IgGs, Transferrin, 
Fibrinogen, Immunoglobulin A (IgAs), Alpha-
2-Macroglobulin, IgMs(Immunoglobulin M), 
Alpha-1-Antitrypsin, Complement C3, C4 & 
C1q, Haptoglobin, Apolipoprotein A1, 
Apolipoprotein A2, Apolipoprotein B, Acid-1-
Glycoprotein, Ceruloplasmin, IgDs 
(Immunoglobulin D), Prealbumin, Plasminogen. 
Then using 2D-CleanUp Kit and according to 
its direction, remaining proteins were purified 
and precipitated and this precipitate was solved 
in rehydration solution. Then using 2D Quant 
Kit and according to its direction, protein 
concentration of rehydration solution was 
determined. Then 2-dimensional 
electrophoresis (2-DE) was done. 
2-DE technique 
     For all samples, 2-DE analysis was done 
with triple repeat. First dimension was done 
using BIO RAD PROTEAN IEF Cell, 7 cm 
IPG with pH range 3-10. IsoElectric Focusing 
(IEF) was done in-gel and 30 µg protein was 
 




loaded for each gel. For second dimension, Bio 
Rad Electrophoresis Tank was used. For this 
step, 12% SDS-PAGE gel was prepared. After 
electrophoresis completed, gels were stained 
using silver nitrate and scanned using GS-800 
Calibrated Densitometer and documented. 
Densitometric analysis of images and statistic 
evaluation of spots 
    For bioinformatic analysis, Progenesis 
SameSpots ver.4 software was used. For 
representing the proteome pattern, a reference 
gel (figure 1) was selected.  
Then using this software, changes in 
expression of proteins in healthy and 
preeclamptic states were analyzed. The entire 
data was presented as ± 2 standard deviation 
(SD). Statistic significance was analyzed using 
t-test and p-values below 0.05 were considered 
statistically significant. 
 
Matrix Assisted Laser Desorption/Ionization 
Time of Flight (MALDI-TOF MS) analysis 
    Using spot picker, protein spots were picked 
up and transferred to York University in 
England. Protein bands were destained using 
acetonitrile , and using dithiotreitol (DTT) and 
iodoacetamide were reduced and alkylated 
respectively and were trypsinized in 37ºC for 24 
hours. Finally, the extracted peptides were 




     The general information of studied 
population is mentioned in table 1. Statistical 
analysis for 33 gels of control group and 33 gels 
of case group was done. After selection of 
reference gel (figure 1) and statistical analysis, 
303 spots were seen. 
 
Figure 1. Reference 2-DE gel ofhealthy pregnant women 16
th
 week plasma.303 spots were detected. 
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Figure 2. Expression decrease plot of spot No. 153 and it's location. (A) location of spot No. 153  on gels of healthy and 
preeclamptic state. (B) Expression difference of VDBP in healthy (purple, 4.2±1.65) and  preeclamptic (blue, 3.97±0.28) 
states. Results are represented as expression difference ± 2SD. 
 
Table 1. Studied population general information using Mean (SD). 




Maternal Age (years) 28 (1.6) 29.56 (3.7) 0.357 
Systolic Blood Pressure During 16 week of gestation (mm Hg) 103.33 (10) 110 (17) 0.399 
Diastolic Blood Pressure During 16 week of gestation (mm Hg) 76.67 (5) 76.67 (5) 1 
Maximum Systolic Blood Pressure During Pregnancy (mm Hg) 125 (5) 158.89 (8) 0.000 
Maximum Diastolic Blood Pressure During Pregnancy (mm Hg) 70 (0) 90 (0)  
BMI (kg.m
-2
) 24.050 (2) 25.144 (2.4) 0.379 
Fetal Results    
Delivery Gestational Age (week) 39 (0) 39.11 (0.3) 0.435 
Birth Weight (kg) 3.45 (0.12) 3.18 (0.3) 0.63 
 








weight  (kDa) 




51 5.33 0.047 
 
Among these 303 spots, density of 2 spots was 
statistically different (significant) between the 
case and control groups. These 2 spots were No. 
153 and 197. Density of both spots or 
expressions of these proteins were decreased in 
case group or PE condition. These 2 spots, 153 
and 197, were determined using MALDI-TOF 
MS. The spot No. 153 (p-value: 0.047) was 
vitamin D-binding protein (table 2) and the 
other one will be revealed in another paper. 
The location of this spot and change in its 
expression level is shown in figures 2. In part A 
of figure 2, a section of final gel for case and 
control groups is shown. In part B of figure 2, 
numbers on the plot represent amount of spot 
density or protein expression. For normalization 
and deleting highly varied data, the vertical axis 
is based on log. For normalization, spot density 
is divided by total density of the gel spots, so it 
has no unit.  
 
DISCUSSION 
     This is the first investigation exclusively 
done for late-onset PE without IUGR during 
16
th
 week of gestation. Using MALDI-TOF MS, 
2 spots were identified. Because of the 
gestational week and phenotype studied, studied 
population, i.e., Iranian pregnant women, whom 
according to primipaternity theory, pregnancy 
pattern is similar to pregnancy pattern of most 
of the world, and also, the technique used, is 
done for the first time in the world.  
Spot No. 153 was vitamin D binding protein 
(DBP or VDBP, Gc-globulin, Group-Specific 
Component) and serum amyloid P component. 
Vitamin D binding protein, belongs to serum 
 




albumin family, this family includes serum 
albumin, afamin, α-fetoprotein and vitamin D 
binding protein. This protein also migrates as 
an α1-globulin. This multifunctional protein 
binds and transports vitamin D and its 
metabolites, endotoxin and fatty acids in 
plasma and by binding to actin monomers, 
prevents its polymerization, this complex is 
rapidly cleared from bloodstream and 
therefore, the thrombotic effects of actin will 
be blocked [35-37]. 85-90% of plasma vitamin 
D and its metabolites is bound to VDBP [38, 
39] and therefore slows its metabolism [40]. Its 
molecular weight and length are 51243 Da and 
458 amino acids, respectively. Its plasma 
concentration is 20-55 mg/dl and its plasma 
half-life is approximately 2.5 days [41,42]. 
This protein is mainly synthesized in liver and 
is the main reservoir of vitamin D sterols. This 
plasma protein also presents in amniotic fluid 
[43, 44]. Also, expression of this protein on the 
surface of placental trophoblasts has been 
reported [45]. Three electrophoretic variants of 
this protein include: Gc2, Gc1s and Gc1f. 
Increased levels of this protein occurs in the 
third trimester of pregnancy and in patients 
consuming estrogen oral contraceptives. 
Estrogens increase VDBP plasma levels, 
therefore plasma concentration of this protein 
increases during pregnancy [46, 47]. Also, 
during normal pregnancy, cell-free actin levels 
and therefore, actin-VDBP complex levels are 
increased [48]. Decreased amount of this 
protein occurs in severe liver disease, protein-
losing syndromes and trauma patients 
developed organ dysfunction and sepsis. Gc 
perhaps is important in bone formation and for 
immune system and presumably acts as a co-
chemotactic factor in facilitating chemotaxis of 
neutrophils and monocytes in inflammation. 
This protein is also an acute phase reactant, 
although it is controversial [49, 50]. 
In this study, there is a 1.6 fold decrease of 
VDBP expression in case group or 
preeclamptic state. In a nested case-control 
study, blood levels of VDBP were measured. 
In this study, sampling was done during first 
trimester and was not done for a specific 
phenotype of PE. The levels of VDBP were 
similar in case and control group [51]. In 
another study, levels of actin-free VDBP 
(AFVDBP) were measured for early and late-





 trimester of PE pregnancies 
but increased during the first trimester of PE 
pregnancies, presumably due to inflammatory 
process normally occurs during pregnancy 
[52]. In another study, sera of pregnant women 
with severe preeclampsia and healthy pregnant 
women were analyzed using 1D Gel-LC-
MS/MS, phlebotomy was done during disease 
presentation. 51 proteins were differentially 
expressed, among them; VDBP was up-
regulated [53]. Results of these three studies 
were controversial. However, in another study, 
auto-antibodies against two placental proteins 
has been reported: annexin A1 and VDBP. 
Subjects were Iranian pregnant women and 
study was done for late-onset PE [54]. 
Decreased VDBP in plasma of case group or 
preeclamptic patients may indicate increased 
placental tissue damage, because the protein is 
present in placental tissue. This damage may 
be a result of auto-immune response. Presence 
of VDBP polymorphisms may support this 
idea. According to primipaternity theory of 
preeclampsia, mother produces antibodies 
against father's antigens expressed in placental 
tissue. This phenomenon occurs in developing 
countries in which sexual intercourse between 
couples before marriage is rare, therefore, 
mother's tolerance against father's antigens is 
low [55, 56]. Our study and Gharesi-Fard 
study, both was performed on Iranian pregnant 
women with above mentioned pattern for 
marriage. There is a convergence between our 
study and Gharesi-Fard et al. study in two 
aspects: the protein involved in disease, i.e., 
VDBP, and the population studied, i.e., Iranian 
pregnant women. This may be indicative of 
culture effect on pregnancy patterns [55, 56] 
and it should be considered in study design. 
However, may be autoantibodies attach to 
VDBP and promote its clearance from 
bloodstream. According to above mentioned 
material, VDBP is a placental tissue protein, 
and there is a defect in placentation in PE 
pathogenesis, therefore, there is a consistence 
between decrease in VDBP and PE. Another 
point is that vitamin D deficiency is a risk 
factor for PE and hypertensive conditions [57, 
58] and theoretically, decrease in VDBP is 
associated with decrease in vitamin D, i.e., the 
reservoir of vitamin D decreases [57, 59]. 
 




According to this point, decrease in VDBP 
expression is consistent with PE pathology. 
CONCLUSION 
     In this study, first parity average age of case 
and control group reflects the limitation of 
pregnancy opportunity for this population that 
represents the importance of pregnancy care, of 
which prediction and diagnosis of diseases are 
its important aspects. According to results, PE 
pathogenesis is present in 16
th
 week of 
gestation; therefore PE can be predicted or may 
be prevented. In this period, placental tissue 
damage may be present; therefore tissue 
damage markers may be helpful for prediction 
of PE. Also immunity against father’s antigens 
may be a cause of disease that implies the effect 
of culture on pregnancy pattern. Altered vitamin 
D metabolism may be a result of PE 
pathogenesis rather than a cause. Generally, it 
seems that a complex of above mentioned 
causes is involved in disease physiopathology 
and this marker is specific enough for PE 
prediction. Further investigation should be done 
for screening biomarker determination for PE. 
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